Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Finerenone shields against pneumonia, COVID-19 in diabetic patients with CKD
Finerenone shields against pneumonia, COVID-19 in diabetic patients with CKD
02 Nov 2022 bởiJairia Dela Cruz

Patients with concomitant chronic kidney disease (CKD) and type 2 diabetes (T2D) who are undergoing mineralocorticoid receptor blockade with finerenone are better protected against pneumonia and COVID-19, according to a secondary analysis of data from the FIDELITY trials.

Finerenone shields against pneumonia, COVID-19 in diabetic patients with CKD
02 Nov 2022
Carbapenem-sparing cephamycins effective in E coli-induced UTI
Carbapenem-sparing cephamycins effective in E coli-induced UTI
28 Oct 2022
COVID-19 worsens antibiotic resistance
COVID-19 worsens antibiotic resistance
28 Oct 2022
B/F/TAF safe, effective in adults with high HIV-1 RNA, low CD4 count
B/F/TAF safe, effective in adults with high HIV-1 RNA, low CD4 count
27 Oct 2022 bởiStephen Padilla

Adults with a high baseline HIV-1 RNA or low CD4 count may benefit from initial treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), which has been shown to be safe and efficacious over 5 years of follow-up in a study presented at the ID Week 2022 Virtual Conference.

B/F/TAF safe, effective in adults with high HIV-1 RNA, low CD4 count
27 Oct 2022
Ridinilazole triggers clinical response in CDI, inhibits recurrence
Ridinilazole triggers clinical response in CDI, inhibits recurrence
27 Oct 2022 bởiTristan Manalac

In patients with Clostridioides difficile infections (CDI), treatment with ridinilazole (RDZ) leads to high and sustained rates of clinical response, according to a study presented at the recently concluded Virtual ID Week 2022. Compared with vancomycin (VAN), RDZ also more strongly prevents recurrent CDI (rCDI).

Ridinilazole triggers clinical response in CDI, inhibits recurrence
27 Oct 2022
COVID-19 oral antivirals reduce in-hospital mortality and healthcare utilization in real-world setting
COVID-19 oral antivirals reduce in-hospital mortality and healthcare utilization in real-world setting
27 Oct 2022 bởiChristina Lau

Use of molnupiravir or nirmatrelvir/ritonavir in high-risk patients with mild-to-moderate COVID-19 is associated with reduced in-hospital mortality, reduced hospital admissions or readmissions, and potential healthcare cost savings, according to a real-world retrospective cohort study led by researchers from the Chinese University of Hong Kong and the University of Hong Kong.

COVID-19 oral antivirals reduce in-hospital mortality and healthcare utilization in real-world setting
27 Oct 2022
Higher hospital staffing tied to better COVID-19 survival
Higher hospital staffing tied to better COVID-19 survival
27 Oct 2022
Statins show therapeutic potential in COVID-19-related acute kidney injury
Statins show therapeutic potential in COVID-19-related acute kidney injury
26 Oct 2022 bởiJairia Dela Cruz

COVID-19 patients with chronic statin exposure appear to be at lower risk of developing acute kidney injury (AKI) during hospitalization in addition to having reduced levels of inflammation, as reported in a study.

Statins show therapeutic potential in COVID-19-related acute kidney injury
26 Oct 2022